Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

(40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP 300 MG / 100 ML

SODIUM CHLORIDE : 300 MG / 100 ML POTASSIUM CHLORIDE : 300 MG / 100 ML DEXTROSE : 3.3 G / 100 ML · DIN 00438022 · BAXTER CORPORATION

Health Canada status: MARKETED

What is (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP?

(40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP 300 MG / 100 ML contains SODIUM CHLORIDE : 300 MG / 100 ML POTASSIUM CHLORIDE : 300 MG / 100 ML DEXTROSE : 3.3 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00438022, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 21-Jan-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP used for?

Potassium Chloride in Dextrose and Sodium Chloride Injection, USP is indicated as a source of water, electrolytes and calories. Dextrose-containing solutions may also be indicated in clinical conditions where enteral nutritional supply is or is expected to be insufficient or impossible.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN00438022
Brand name(40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP
Generic / active ingredientSODIUM CHLORIDE : 300 MG / 100 ML POTASSIUM CHLORIDE : 300 MG / 100 ML DEXTROSE : 3.3 G / 100 ML
ManufacturerBAXTER CORPORATION
Strength300 MG / 100 ML
Dosage formSOLUTION
Route of administrationINTRAVENOUS
ScheduleEthical
ATC codeB05BB02 ELECTROLYTES WITH CARBOHYDRATES
AHFS class40:12.00 ; 40:20.00
BiosimilarNo
Health Canada statusMARKETED
Status date21-Jan-2013
Original market date1978-12-31 00:00:00

How is it administered?

For intravenous infusion. Dosage, rate, and duration depend on age, weight, clinical/metabolic conditions, and concomitant therapy as directed by a physician. Use of an in-filter is recommended.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 15°C to 25°C. Avoid excessive heat.

How is it supplied?

Available as per Table 1 (Dosage Forms and Packaging information is missing from the provided text).

Contraindications

Clinically significant hyperglycemia or hyperkalemia; hypersensitivity to the drug, container components, or corn/corn products.

Warnings and precautions

Risk of fluid/solute overload, hyponatremia, hyperkalemia, and hyperglycemia. Do not administer simultaneously with blood through the same set (risk of pseudoagglutination/hemolysis).

What can be used instead?

Other Canadian products sharing ATC code B05BB02 ELECTROLYTES WITH CARBOHYDRATES. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
(20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP3.3 G / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00438014
(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP150 MG / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00786292
(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP150 MG / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00438049
(20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP5 G / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00437999
(40 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP300 MG / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00438030
(40MMOL/L)POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP300 MG / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00438006
0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP5 G / 100 MLSOLUTIONB. BRAUN MEDICAL INCMARKETEDDIN 01931598
5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP5 G / 100 MLSOLUTIONB. BRAUN MEDICAL INCMARKETEDDIN 01927531
5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP50 MGSOLUTIONB. BRAUN MEDICAL INCMARKETEDDIN 01924435
DEXTROSE 10% AND 0.9% SOD CHLORIDE INJ900 MG / 100 MLSOLUTIONBAXTER CORPORATIONMARKETEDDIN 00060755

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP

Health Canada Drug Product Database (DPD), DIN 00438022. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.